CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Moderna Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Moderna Inc
325 BINNEY STREET
Phone: (302) 658-7581p:302 658-7581 Cambridge, MA  02142  United States Ticker: MRNAMRNA
Business Summary
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board, Co-Founder Noubar B.Afeyan 63 2/1/2012 1/1/2010
President StephenHoge 49 2/1/2015 2/1/2015
Chief Executive Officer, Director StephaneBancel 53 10/1/2011 3/1/2011
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MODERNA BIOTECH UK LIMITED 2ND FLOOR 31 CHERTSEY STREET GUILDFORD UK
MODERNA SWITZERLAND GMBH AESCHENVORSTADT 48 BASEL BS

Business Names
Business Name
Moderna Australia Pty Ltd
Moderna Biopharma Canada Corporation
Moderna Biotech Distributor UK Ltd.
26 additional Business Names available in full report.

General Information
Number of Employees: 4,700 (As of 12/31/2025)
Outstanding Shares: 396,586,862 (As of 3/9/2026)
Shareholders: 62
Stock Exchange: NASD
Federal Tax Id: 813467528
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 12, 2026